Lisata Therapeutics, based in Basking Ridge, New Jersey, focuses on developing therapies for advanced solid tumors, with its lead candidate LSTA1 enhancing anti-cancer drug penetration in tumors. The company also explores CD34+ cell therapy for various diseases, including critical limb ischemia and diabetic kidney disease.
LSTA has been in the news recently: Alamar Biosciences will showcase over 30 studies on neurodegenerative disease biomarkers using its NULISA™ platform at the AAIC conference from July 27-31, 2025, in Toronto. The company is collaborating with DZNE to analyze 23,000 plasma samples with its NULISAseq™ panels to enhance biomarker discovery related to aging and neurodegeneration.
📡️ Health Care
In The News
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
